This paper establishes nonparametric formulas that can be used to bound the average treatment e ect in experimental studies in which treatment assignment is random but subject compliance is imperfect. The bounds provided are the tightest possible, given the distribution of assignments, treatments, and responses. The formulas show that even with high rates of noncompliance, experimental data can yield useful and sometimes accurate information on the average e ect of a treatment on the population.
INTRODUCTION
Consider an experimental study where random assignment has taken place but compliance is not perfect i.e., the treatment received di ers from that assigned. It is well known that under such conditions a bias may b e i n troduced. Subjects who did not comply with the assignment m a y be precisely those who would have responded adversely positively to the treatment; therefore, the actual e ect of the treatment, when applied uniformly to the population, might be substantially less more e ective than the study reveals.
In an attempt to avert this bias, analysts sometimes resort to parametric models which make restrictive commitments to a particular mode of interaction between compliance and response Efron and Feldman 1991. Angrist et al. 1996 have identi ed a set of assumptions under which a nonparametric correction formula, called Instrumental Variables", is valid for certain subpopulations. Since these subpopulations cannot be identi ed from empirical observation alone, the need remains to devise alternative, assumption-free formulas for assessing the e ect of treatment over the population as a whole. Robins 1989 and To appear in JASA.
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PROBLEM FORMULATION
The canonical partial-compliance setting can be graphically modeled as shown in Figure 1 . We assume that Z, D, and Y are observed dichotomous variables where Z represents the randomized treatment assignment, D is the treatment actually received, and Y is the observed response. U represents speci c characteristics of an individual subject, namely, all factors, both observed and unobserved, that in uence the way a subject's outcome Y may depend on the treatment D. The experimental study is modeled as a two-step process 1 treatment selection and 2 treatment administration. In the rst step, each subject is allowed to select a treatment in accordance with the following factors: the assignment Z , basic physiological characteristics U, and possibly, initial reactions to the treatment or placebo. Such reactions are not shown explicitly in the graph, since they merely modify the in uence of Z and U on D, and the diagram makes no assumption as to the nature of this in uence. Once the treatment D is selected, the treatment administration step begins, during which subjects are assumed to remain within their selected treatment arms until the outcome Y is recorded; back and forth switching between placebo and active groups is not allowed at this stage.
Given this two-stage process, the second assumption is that the assignment Z per se does not alter any p h ysiological characteristics U which determine how an individual would react to any given treatment. This assumption, which Angrist et al. 1996 named exclusion restriction" and Manski 1990 called set-level restriction" is represented in the causal diagram of Figure 1 . This independence is partly ensured through the randomization of Z, which rules out a common cause for both Z and U , and partly through our second assumption above that physiological factors U are not in uenced by the assignment Z . These two independencies impose on the joint distribution the decomposition P y; d; z; u = P yjd; uP djz;uPzPu which, of course, cannot be observed directly because U is unmeasurable. We take the liberty of denoting the prior distribution of U by P u, even though U may consist of continuous variables. However, the marginal distribution P y; d; z and, in particular, the conditional distributions P y;djz = X u P yj d; uP djz;uPu 1 z 2 fz 0 ; z 1 g , are observed, and these observations constrain the factor P yjd; uP u to produce bounds on treatment e ects. Treatment e ects are characterized by a distribution P yj d which stands for the probability that Y would have been equal to y, i f D w ere equal to d under a randomized experiment. In general, a value annotated with a check will indicate that the corresponding variable has been set to that value by a randomized control. Angrist et al. 1996 and Holland 1988 denoted this distribution by P Y D=d , but we nd the check" notation more exible, as it permits one to specify explicitly what is controlled and what is allowed to vary in any given study Pearl 1995a. Thus, to assess the distribution of Y if the treatment D were applied uniformly to the population, we should calculate Our task is then to estimate or bound the expressions in 2 and 3, given the observed probabilities P y;djz 0 and P y;djz 1 , as expressed in 1. This may b e accomplished by a procedure detailed in Balke and Pearl 1994 , which is based on linear programming optimization coupled with the fact that the domain of U can be partitioned into sixteen equivalence classes, each representing one of four possible mappings from Z to D conjoined with one of four possible mappings from D to Y .
RESULTS
Let the conditional distribution P y;djz o v er the observed variables be denoted as follows: Optimization of 2 subject to the equality constraints given in 1 de nes a linear programming problem that yields a closed-form solution by e n umerating all vertices of the constraint polygon of the dual problem. This procedure leads to the following bounds: max Robins 1989 and Manski 1990 , which correspond to the four upper terms in both 4 and 5. One can show that the width of the bounds in 4 and 5 cannot exceed the rate of noncompliance, P d 1 jz 0 + P d 0 j z 1 , and may in some cases collapse to a point estimate, even when as many as 50 of subjects switch o v er to unassigned treatments Pearl 1995b. Precise determination of treatment e ects is feasible whenever a the percentage of subjects complying with assignment z 0 is the same as those complying with z 1 and b in at least one treatment arm d; y and z are perfectly correlated.
This, and other results regarding bounds on treatment e ects in partial compliance studies are elaborated in Balke and Pearl 1993 and Balke 1995 . In particular, it is shown that the basic structural assumptions underlying randomized-assignment experiments, although not directly testable, imply testable restrictions on the observed distributions. By requiring that no upper bound be less than the corresponding lower bound, we obtain If any of these inequalities is violated, the investigator can deduce that either the assignments were not properly randomized, or the assignment exerted some direct in uence on subjects' responses. These inequalities, when generalized to multivalued variables, assume the simple form The instrumental inequality can be further tightened if additional assumptions are made about subjects' behaviors, for example, that no individual would consistently act contrarian to his her assignment, or, mathematically, that for all u we h a v e P d 1 j z 1 ; u P d 1 j z 0 ; u Under this assumption, which Angrist et al. 1996 call monotonicity, the inequalities in 6 can be tightened Balke and Pearl 1993 for all y 2 f y 0 ; y 1 g . The monotonicity assumption can sometimes be veri ed or enforced empirically, for example, by making sure that no subject in the placebo group gains access to active treatment. In such cases, 7 provides more stringent tests for the model assumptions. However, in cases where monotonicity cannot be ensured, violation of the inequalities in 7 may mean that randomization of Z w as imperfect, Z had a direct e ect on Y , or contrarian subjects were present.
It can also be shown Balke and Pearl 1993 that, when monotonicity holds, the bounds in 4 and 5 reduce to those derived by Robins 1989 and Manski 1990 rst four entries in 4 and 5, and the width coincides precisely with the rate of noncompliance,
Finally, the method of causal analysis outlined above permits one to evaluate a wide variety of counterfactual probabilities, for example, the probability that a given individual would have recovered had he she not been assigned treatment z 0 , when in actuality he she has been assigned the treatment z 1 , taken the treatment d 1 , and not recovered y 0 . This When the treatment i s c o n tinuous, few subjects, if any, would take o n a n y given level of treatment precisely. However, it is reasonable to assume that there exists a treatment interval around each d, within which a subject's outcome is, for all practical purposes, homogeneous. In other words, for every u we h a v e: P yjd 0 ; u P y j d 
EXAMPLES 4.1 Vitamin A Supplementation
Consider the study of Vitamin A supplementation in northern Sumatra described by Sommer et al. 1986 and Zeger 1991 . In this study, out of 450 villages, 221 were randomly assigned to the control group and the remaining 229 were assigned to the treatment group. In the treatment group, oral doses of Vitamin A were administered to the population at 2 3 months and once again at 6 months; because of government policy, the control group was not administered a placebo. 12 months after the original census the mortality y 0 o f the population was determined from the time at which the initial dose was administered. Table 1 presents the nal subject counts in terms of our partial compliance model notation. Table 2 : Conditional probability distribution P y;djz derived from the data in Table 1 .
If we make the large-sample assumption and take the sample frequencies as representing P y;djz, then Table 2 presents the probability distribution estimated from the counts in Table 1 . which is rather revealing: Vitamin A supplement, if uniformly administered, is seen capable of increasing mortality rate by m uch as 19.46, and is incapable of reducing mortality rate by more than 0.54. The intent-to-treat analysis might mislead one to believe that Vitamin A supplement has a bene cial e ect of P y 1 jz 1 ,P y 1 jz 0 = 0 : 0026, in total oblivion to the danger presented at the lower end of the range. The IV estimand advocated in Angrist et al. 1996 calculates to 0.0035, which further exaggerates the illusionary bene ts of Vitamin A supplement. The techniques described in Balke and Pearl 1994 may also be used to nd a population mix that would explain a particular value of the causal e ect magnitude. For example, one may wish to inquire: What behavioral characteristics, consistent with the observed data, would support a detrimental e ect of ACED ! Y = , 0 : 1946 shown possible at the extreme lower end of the range. For the most part, the population under study would have to be composed of two homogeneous groups. In one group, consisting of almost 80 percent of the population, all subjects would survive regardless of treatment and would perfectly comply with their treatment assignment. In the other group, consisting of almost 20 percent of the population, subjects would die if and only if they take Vitamin A supplements and, not surprisingly, these subjects would refuse Vitamin A supplements under the conditions prevailing in the study. The ability to associate a population mix with any ACE value provides a vantage point from which the plausibility of that ACE value can be assessed. Table 3 : Conditional probability distribution P y;djz for the Lipid Research Clinic Program 1984 data, made discrete by 8 and 9.
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a parametric model; this same data set will be used in our analysis. A population of subjects was assembled and two preliminary cholesterol measurements were obtained: one prior to a suggested low-cholesterol diet continuous variable C I1 ; and one following the diet period C I2 . The initial cholesterol level C I was taken as a weighted average of these two measures: C I = 0:25C I1 + 0 : 75C I2 . The subjects were randomized into two treatment groups; in the rst group all subjects were prescribed cholestyramine z 1 , while the subjects in the other group were prescribed a placebo z 0 . During several years of treatment, each subject's cholesterol level was measured multiple times, and the average of these measurements was used as the post-treatment cholesterol level continuous variable C F . The compliance of each subject was determined by tracking the quantity of prescribed dosage consumed continuous variable B. The maximum consumption in the data set was 101 units. In order to apply our analysis to this study, the continuous data obtained in the Lipid Research Clinic Program 1984 study is made discrete in the following way: Table 3 we make the large-sample assumption and take the sample frequencies as representing P y;djz. which is quite informative; the experimenter can categorically state that when applied uniformly to the population, a dosage of 84 to 101 units of cholestyramine is guaranteed to increase by at least 26:2 the probability of reducing a patient's level of cholesterol by 3 8 points or more. This guarantee is established despite the fact that 60:6 of the subjects in the treatment group did not comply with their assigned dosage level. For comparison, note that the intent-to-treat analysis in this study gives P y 1 jz 1 , P y 1 jz 0 = 0 : 408, meaning that enforcing full compliance might result in as much as 46 improvement and no more than 14:6 reduction in the proportion of patients bene ting from the treatment.
CONCLUSION
In an attempt to avert confounding bias in randomized studies involving noncompliance, analysts usually advocate the use of intent-to-treat" analysis, which compares assignment groups regardless of the treatment actually received. Estimates derived by such analysis are free of confounding bias, but decisions based on these estimates require that the experimental conditions perfectly mimic the conditions prevailing in the eventual usage of the treatment.
In particular, the intent-to-treat analysis is inappropriate when the inducement to receive treatment changes from what it was in the study, for example, when a drug is o cially endorsed by a w ell-meaning authority. A similar weakness applies to the analysis of Angrist et al. 1996 who derive causal e ect formulas for the unobservable subpopulation of responsive" subjects, that is, subjects who would have c hanged treatment status if given a di erent assignment. This subpopulation cannot serve as a basis for policy analysis because it is instrument dependent | individuals who are responsive in the study may not remain responsive in the eld, where the incentives for obtaining treatment di er from those used in the study.
In policy evaluation studies, eld incentives are normally more compelling than experimental incentives; hence, treatment e ectiveness should be assessed by the average causal e ect, E u P y 1 ju; d 1 , P y 1 ju; d 0 for which w e h a v e provided sharp theoretical bounds.
Estimates based solely on intent-to-treat analysis, as well as those based on instrumental variables, can be misleading as they may lie entirely outside the theoretical bounds. The formulas established in this paper provide instrument-independent guarantees for policy analysis and, in addition, should enable analysts to determine the extent to which e orts to enforce compliance may increase the overall treatment e ectiveness.
A topic that should receive considerable attention in future work is the augmentation of the bounds in 4-5 with con dence intervals, to account for sample variability. Chickering and Pearl 1996 describe a Bayesian method which, using Gibbs sampling, computes the posterior distribution of ACED ! Y given the data. An alternative approach in this direction is o ered by the maximum-likelihood ratio test, as applied to the hypothesis H 0 : ACED ! Y t , for arbitrary t, since the maximum likelihood function under H 0 can be computed using linear programming.
